Literature DB >> 18161887

Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer.

F Peintinger1, H M Kuerer, S E McGuire, R Bassett, L Pusztai, W F Symmans.   

Abstract

BACKGROUND: Neoadjuvant chemotherapy for breast cancer reduces tumour cellularity, the percentage of the primary tumour area that is composed of invasive tumour cells. Minimal residual tumour cellularity (5 per cent or less of tumour area composed of invasive tumour cells) may be associated with an increased risk of false-negative intraoperative margins. The aim of this study was to evaluate the incidence of minimal residual tumour cellularity after neoadjuvant chemotherapy and its impact on the frequency of false-negative margins and conversion from breast-conserving surgery to mastectomy.
METHODS: The final pathology slides of 510 patients who had surgery after neoadjuvant chemotherapy were reviewed.
RESULTS: Of 396 patients with residual invasive breast cancer after neoadjuvant chemotherapy, 100 specimens (25.3 per cent) had minimal residual cellularity; this was more frequent in patients with invasive lobular carcinoma (17.0 versus 5.1 per cent; P < 0.001) or well and moderately differentiated carcinoma (68.0 versus 52.4 per cent; P = 0.007). Among 149 patients who had initial breast-conserving surgery, false-negative intraoperative margin rates were 23 per cent in specimens with minimal and 13.8 per cent in those with higher residual cellularity (P = 0.210). There was no significant difference in the rate of conversion to mastectomy between the groups.
CONCLUSION: Minimal residual cellularity after neoadjuvant chemotherapy occurred in about 25 per cent of specimens, but did not alter the rate of false-negative intraoperative margins. 2007 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 18161887     DOI: 10.1002/bjs.6044

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  5 in total

1.  Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.

Authors:  Aida Kuzucan; Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Peter T Fwu; Hon J Yu; David J B Hsiang; Karen T Lane; John A Butler; Stephen A Feig; Min-Ying Su
Journal:  Clin Breast Cancer       Date:  2012-04       Impact factor: 3.225

2.  Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.

Authors:  Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Aida Kuzucan; Hon J Yu; Philip M Carpenter; Stephen A Feig; Muqing Lin; David J B Hsiang; Karen T Lane; John A Butler; Orhan Nalcioglu; Min-Ying Su
Journal:  Radiology       Date:  2011-08-30       Impact factor: 11.105

Review 3.  Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.

Authors:  V Bossuyt; E Provenzano; W F Symmans; J C Boughey; C Coles; G Curigliano; J M Dixon; L J Esserman; G Fastner; T Kuehn; F Peintinger; G von Minckwitz; J White; W Yang; S Badve; C Denkert; G MacGrogan; F Penault-Llorca; G Viale; D Cameron
Journal:  Ann Oncol       Date:  2015-05-27       Impact factor: 32.976

4.  Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?

Authors:  Helena Earl; Elena Provenzano; Jean Abraham; Janet Dunn; Anne-Laure Vallier; Ioannis Gounaris; Louise Hiller
Journal:  BMC Med       Date:  2015-09-22       Impact factor: 8.775

5.  Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors.

Authors:  Shushu Wang; Yi Zhang; Xinhua Yang; Linjun Fan; Xiaowei Qi; Qingqiu Chen; Jun Jiang
Journal:  World J Surg Oncol       Date:  2013-07-24       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.